Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

  • STATUS
    Recruiting
  • days left to enroll
    38
  • participants needed
    29
  • sponsor
    University Hospital, Akershus
Updated on 23 January 2021
neutrophil count
docetaxel
ifosfamide
high dose chemotherapy
germ cell tumor
germ cell cancer
salvage treatment

Summary

Germ cell tumors belong to the most chemosensitive malignancies. Paclitaxel in combination with ifosfamide and cisplatin (TIP) has become a common regimen for salvage treatment of germ cell cancer.

Cabazitaxel may overcome resistance to docetaxel and paclitaxel and might have clinical activity in patients with metastatic and progressive germ cell tumors.

Description

Patients with metastatic germ cell cancer and relapse after two or more courses of cisplatin-based chemotherapy or after high-dose chemotherapy have a poor prognosis and no curative options. Taxanes in various combinations unfold cytotoxic effects on germ cell tumors resistant to conventional doses of cisplatin. Paclitaxel in combination with ifosfamide and cisplatin (TIP) has become a common regimen for salvage treatment of germ cell cancer. In most patients, however, resistance to paclitaxel, as evidenced by progression occurs.Cabazitaxel has been developed to overcome resistance to docetaxel and paclitaxel. It has shown efficacy in patients progressing during docetaxel therapy in a large phase III trial (TROPIC) in patients with castration-resistant prostate cancer. Furthermore, chemotherapy resistance might be less likely to develop in patients receiving cabazitaxel as compared to other taxanes.

Details
Condition Malignant neoplasm of testis, Testicular Cancer, testis cancer
Treatment Cabazitaxel
Clinical Study IdentifierNCT02478502
SponsorUniversity Hospital, Akershus
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male patients 18 years old
Histologically verified metastatic germ cell cancer (GCC) of the testicle or extragonadal GCC originating from retroperitoneum or mediastinum
Disease progression during cisplatin-based chemotherapy or Disease progression or relapse after high-dose chemotherapy or Disease progression or relapse after at least 2 different cisplatin-based regimens
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-2
Life expectancy 3 months
At baseline adequate function of liver, kidneys and bone marrow
Neutrophils 1.5 x 109/L
Hemoglobin 9.0 g/dL
Platelets 100 x 109/L
Creatinine 1.5 x upper limit of normal (ULN)
Total Bilirubin 1.0 x ULN
Serum glutamate oxaloacetate transaminase (SGOT/AST) 1.5 x ULN
Serum glutamate pyruvate transaminase (SGPT/ALT) < 1.5 x ULN

Exclusion Criteria

Systemic antitumor treatment within 21 days before study entry
Simultaneous radiotherapy to the only target lesion
Patients unwilling or unable to comply with the protocol
Patients with unstable angina pectoris, myocardial infarction 6 months prior to first study treatment, congestive heart failure New York Heart Association (NYHA) III-IV or serious uncontrolled cardiac arrhythmias
Patients with an active or uncontrolled infection
Patients who have a history of another primary malignancy and are off treatment for 3 years, with the exception of non-melanoma skin cancer
Patients who have undergone major surgery within 4 weeks prior to starting study drug (e.g. intra-thoracic, intra-abdominal, or intra-pelvic) or significant traumatic injury, or who have not recovered from the side effects of any of the above within 6 weeks
Patients who have participated in another interventional clinical trial within 30 days before study entry
Other serious medical conditions that could impair the ability of the patient to participate in the study
Active infection requiring systemic antibiotic-, anti-viral-, or anti-fungal medication
Neuropathy Grade 2 Common Terminology Criteria for Adverse Events (CTCAE)
Patient with reproductive potential not implementing accepted and effective method of contraception during the whole study period and up to 6 months after the last dose of cabazitaxel
One or more of the following cabazitaxel-specific requirements
History of severe hypersensitivity reaction ( Grade 3) to docetaxel
History of severe hypersensitivity reaction ( Grade 3) to polysorbate 80 containing drugs
Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4 (CYP3A4) (a one week wash-out period is necessary for patients who are already on these treatments) (see Appendix A and B)
Concurrent or planned treatment with Organic anion transporting polypeptide1B1 (OATP1B1) substrates e.g. statins, valsartan, repaglinide which have to be taken within 12 hours before cabazitaxel application and 3 hours after the end of infusion, refer table 9
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note